[Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations].
Pharmacokinetics and absolute bioavailability of 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (bromopride, Viaben), in various preparations (bromopride injection solution, bromopride suppositories for adults, drops and capsules, respectively) in various dosages were calculated. Several investigations were performed: Study I: Absolute bioavailability of bromopride suppositories for adults (cross-over). Study 2: Pharmacokinetics of Bromopride drops after single dose of 15 and 30 mg bromopride as well as after multiple dose of 15 mg bromopride (Confarma). Study 3: Pharmacokinetics of bromopride capsules (Confarma). The chemical analysis was made for all studies with a nearly identical HPLC-method so that the results of the various studies were comparable. The studies led to the following result: The bioavailability of the substance bromopride amounts to about 70% and increases after multiple administration to about 90%. Statistically there is no difference between the bioavailabilities of the individual formulations.
D000328:Adult; D001682:Biological Availability; D002214:Capsules; D006801:Humans; D007700:Kinetics; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D012996:Solutions
D002214:Capsules; D012996:Solutions; C013855:bromopride; D008787:Metoclopramide
Pharmakokinetik und absolute Bioverfügbarkeit von Bromoprid aus verschiedenen pharmazeutischen Formulierungen.